{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T22:22:53Z","timestamp":1787955773169,"version":"build-2784847793"},"reference-count":113,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2022,8,17]],"date-time":"2022-08-17T00:00:00Z","timestamp":1660694400000},"content-version":"vor","delay-in-days":16,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100005339","name":"American Academy of Neurology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005339","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001234","name":"McNair Medical Institute","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100001234","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,12,26]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>Despite improved survival outcomes across many cancer types, the prognosis remains grim for certain solid organ cancers including glioblastoma and pancreatic cancer. Invariably in these cancers, the control achieved by time-limited interventions such as traditional surgical resection, radiation therapy, and chemotherapy is short-lived. A new form of anti-cancer therapy called therapeutic alternating electric fields (AEFs) or tumor treating fields (TTFields) has been shown, either by itself or in combination with chemotherapy, to have anti-cancer effects that translate to improved survival outcomes in patients. Although the pre-clinical and clinical data are promising, the mechanisms of TTFields are not fully elucidated. Many investigations are underway to better understand how and why TTFields is able to selectively kill cancer cells and impede their proliferation. The purpose of this review is to summarize and discuss the reported mechanisms of action of TTFields from pre-clinical studies (both in vitro and in vivo). An improved understanding of how TTFields works will guide strategies focused on the timing and combination of TTFields with other therapies, to further improve survival outcomes in patients with solid organ cancers.<\/jats:p>","DOI":"10.1093\/jmcb\/mjac047","type":"journal-article","created":{"date-parts":[[2022,8,16]],"date-time":"2022-08-16T20:17:44Z","timestamp":1660681064000},"source":"Crossref","is-referenced-by-count":32,"title":["Anti-cancer mechanisms of action of therapeutic alternating electric fields (tumor treating fields [TTFields])"],"prefix":"10.1093","volume":"14","author":[{"given":"Shadi","family":"Shams","sequence":"first","affiliation":[{"name":"Rowan University School of Osteopathic Medicine , Stratford, NJ 08028, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0787-0634","authenticated-orcid":false,"given":"Chirag B","family":"Patel","sequence":"additional","affiliation":[{"name":"Department of Neuro-Oncology, The University of Texas MD Anderson Cancer Center , Houston, TX 77030, USA"},{"name":"Neuroscience Graduate Program, The University of Texas MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences , Houston, TX 77030, USA"},{"name":"Cancer Biology Program, The University of Texas MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences , Houston, TX 77030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,8,16]]},"reference":[{"key":"2023021008583653900_bib1","doi-asserted-by":"crossref","first-page":"vi20","DOI":"10.1093\/neuonc\/noz175.074","article-title":"ACTR-31. The use of TTFields for newly diagnosed GBM patients in Germany in routine clinical care (TIGER: TTFields in Germany in routine clinical care)","volume":"21","author":"B\u00e4hr","year":"2019","journal-title":"Neuro Oncol."},{"key":"2023021008583653900_bib2","doi-asserted-by":"crossref","first-page":"738801","DOI":"10.3389\/fonc.2021.738801","article-title":"Establishment of Tumor Treating Fields combined with mild hyperthermia as novel supporting therapy for pancreatic cancer","volume":"11","author":"Bai","year":"2021","journal-title":"Front. Oncol."},{"key":"2023021008583653900_bib3","doi-asserted-by":"crossref","first-page":"6467","DOI":"10.1158\/1078-0432.CCR-21-0544","article-title":"A Clinical PET imaging tracer ([18F]DASA-23) to monitor pyruvate kinase M2-induced glycolytic reprogramming in glioblastoma","volume":"27","author":"Beinat","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"2023021008583653900_bib4","volume-title":"Biochemistry","author":"Berg","year":"2002","edition":"5th edn"},{"key":"2023021008583653900_bib5","doi-asserted-by":"crossref","first-page":"7362","DOI":"10.1038\/s41598-019-43621-9","article-title":"Tumour-treating fields (TTFields): investigations on the mechanism of action by electromagnetic exposure of cells in telophase\/cytokinesis","volume":"9","author":"Berkelmann","year":"2019","journal-title":"Sci. Rep."},{"key":"2023021008583653900_bib6","doi-asserted-by":"crossref","first-page":"147701","DOI":"10.1103\/PhysRevLett.127.147701","article-title":"Dynamic spin-triplet order induced by alternating electric fields in superconductor\u2013ferromagnet\u2013superconductor josephson junctions","volume":"127","author":"Bobkova","year":"2021","journal-title":"Phys. Rev. Lett."},{"key":"2023021008583653900_bib7","doi-asserted-by":"crossref","first-page":"411","DOI":"10.3389\/fonc.2020.00411","article-title":"Concurrent Tumor Treating Fields (TTFields) and radiation therapy for newly diagnosed glioblastoma: a prospective safety and feasibility study","volume":"10","author":"Bokstein","year":"2020","journal-title":"Front. Oncol."},{"key":"2023021008583653900_bib8","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23041982","article-title":"Genome-wide expression and anti-proliferative effects of electric field therapy on pediatric and adult brain tumors","volume":"23","author":"Branter","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"2023021008583653900_bib9","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.bioelechem.2015.04.006","article-title":"Tumor growth delay by adjuvant alternating electric fields which appears non-thermally mediated","volume":"105","author":"Castellv\u00ed","year":"2015","journal-title":"Bioelectrochemistry"},{"key":"2023021008583653900_bib10","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1016\/S1470-2045(19)30532-7","article-title":"Tumour Treating Fields in combination with pemetrexed and cisplatin or carboplatin as first-line treatment for unresectable malignant pleural mesothelioma (STELLAR): a multicentre, single-arm phase 2 trial","volume":"20","author":"Ceresoli","year":"2019","journal-title":"Lancet Oncol."},{"key":"2023021008583653900_bib11","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1038\/s41420-018-0130-x","article-title":"Tumor Treating Fields increases membrane permeability in glioblastoma cells","volume":"4","author":"Chang","year":"2018","journal-title":"Cell Death Discov"},{"key":"2023021008583653900_bib12","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/s11060-017-2534-5","article-title":"Synergistic inhibition of glioma cell proliferation by Withaferin A and tumor treating fields","volume":"134","author":"Chang","year":"2017","journal-title":"J. Neurooncol."},{"key":"2023021008583653900_bib13","doi-asserted-by":"crossref","first-page":"e149258","DOI":"10.1172\/JCI149258","article-title":"Tumor Treating Fields dually activate STING and AIM2 inflammasomes to induce adjuvant immunity in glioblastoma","volume":"132","author":"Chen","year":"2022","journal-title":"J. Clin. Invest."},{"key":"2023021008583653900_bib14","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.jocn.2016.10.042","article-title":"The effects of tumor treating fields and temozolomide in MGMT expressing and non-expressing patient-derived glioblastoma cells","volume":"36","author":"Clark","year":"2017","journal-title":"J. Clin. Neurosci."},{"key":"2023021008583653900_bib15","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s11060-008-9663-9","article-title":"Dose-intensity temozolomide after concurrent chemoradiotherapy in operated high-grade gliomas","volume":"90","author":"Dall'Oglio","year":"2008","journal-title":"J. Neurooncol."},{"key":"2023021008583653900_bib16","doi-asserted-by":"crossref","first-page":"709","DOI":"10.4049\/jimmunol.2100100","article-title":"T cells retain pivotal antitumoral functions under tumor-treating electric fields","volume":"207","author":"Diamant","year":"2021","journal-title":"J. Immunol."},{"key":"2023021008583653900_bib17","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1007\/s13346-021-01067-5","article-title":"An overview on tumor treating fields (TTFields) technology as a new potential subsidiary biophysical treatment for COVID-19","volume":"12","author":"Farmani","year":"2022","journal-title":"Drug Deliv. Transl. Res"},{"key":"2023021008583653900_bib18","doi-asserted-by":"crossref","first-page":"273","DOI":"10.3747\/co.22.2436","article-title":"Nonsurgical treatment of recurrent glioblastoma","volume":"22","author":"Gallego","year":"2015","journal-title":"Curr. Oncol"},{"key":"2023021008583653900_bib19","doi-asserted-by":"crossref","first-page":"034104","DOI":"10.1063\/5.0008462","article-title":"Thermoplastic microfluidic bioreactors with integrated electrodes to study tumor treating fields on yeast cells","volume":"14","author":"Gencturk","year":"2020","journal-title":"Biomicrofluidics"},{"key":"2023021008583653900_bib20","doi-asserted-by":"crossref","first-page":"e0125269","DOI":"10.1371\/journal.pone.0125269","article-title":"Tumor Treating Fields perturb the localization of septins and cause aberrant mitotic exit","volume":"10","author":"Gera","year":"2015","journal-title":"PLoS One"},{"key":"2023021008583653900_bib21","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1186\/s13014-017-0941-6","article-title":"Tumor treating fields (TTFields) delay DNA damage repair following radiation treatment of glioma cells","volume":"12","author":"Giladi","year":"2017","journal-title":"Radiat. Oncol."},{"key":"2023021008583653900_bib22","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.pan.2013.11.009","article-title":"Mitotic disruption and reduced clonogenicity of pancreatic cancer cells in vitro and in vivo by tumor treating fields","volume":"14","author":"Giladi","year":"2014","journal-title":"Pancreatology"},{"key":"2023021008583653900_bib23","doi-asserted-by":"crossref","first-page":"18046","DOI":"10.1038\/srep18046","article-title":"Mitotic spindle disruption by alternating electric fields leads to improper chromosome segregation and mitotic catastrophe in cancer cells","volume":"5","author":"Giladi","year":"2016","journal-title":"Sci. Rep."},{"key":"2023021008583653900_bib24","doi-asserted-by":"crossref","first-page":"S35","DOI":"10.1053\/j.seminoncol.2014.09.006","article-title":"Alternating electric fields (Tumor-treating fields therapy) can improve chemotherapy treatment efficacy in non-small cell lung cancer both in vitro and in vivo","volume":"41","author":"Giladi","year":"2014","journal-title":"Semin. Oncol."},{"key":"2023021008583653900_bib25","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.3390\/cancers14061568","article-title":"Tumor Treating Fields concomitant with sorafenib in advanced hepatocellular cancer: results of the HEPANOVA phase II study","volume":"14","author":"Gkika","year":"2022","journal-title":"Cancers"},{"key":"2023021008583653900_bib26","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1080\/13696998.2019.1614933","article-title":"Tumor treating fields and maintenance temozolomide for newly-diagnosed glioblastoma: a cost-effectiveness study","volume":"22","author":"Guzauskas","year":"2019","journal-title":"J. Med. Econ"},{"key":"2023021008583653900_bib27","doi-asserted-by":"crossref","first-page":"CNS23","DOI":"10.2217\/cns-2018-0010","article-title":"Estimated lifetime survival benefit of tumor treating fields and temozolomide for newly diagnosed glioblastoma patients","volume":"7","author":"Guzauskas","year":"2018","journal-title":"CNS Oncol"},{"key":"2023021008583653900_bib28","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/BF01053415","article-title":"The role of endothelial cells in tumor invasion and metastasis","volume":"23","author":"Jahroudi","year":"1995","journal-title":"J. Neurooncol."},{"key":"2023021008583653900_bib29","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1007\/s13258-021-01105-z","article-title":"Thymidine decreases the DNA damage and apoptosis caused by tumor-treating fields in cancer cell lines","volume":"43","author":"Jeong","year":"2021","journal-title":"Genes Genomics"},{"key":"2023021008583653900_bib30","first-page":"1423","article-title":"The combination of tumor treating fields and hyperthermia has synergistic therapeutic effects in glioblastoma cells by downregulating STAT3","volume":"12","author":"Jo","year":"2022","journal-title":"Am. J. Cancer Res"},{"key":"2023021008583653900_bib31","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1038\/s41420-018-0106-x","article-title":"Selective toxicity of tumor treating fields to melanoma: an in vitro and in vivo study","volume":"4","author":"Jo","year":"2018","journal-title":"Cell Death Discov"},{"key":"2023021008583653900_bib32","doi-asserted-by":"crossref","first-page":"3684","DOI":"10.3390\/ijms19113684","article-title":"Functional biological activity of sorafenib as a tumor-treating field sensitizer for glioblastoma therapy","volume":"19","author":"Jo","year":"2018","journal-title":"Int. J. Mol. Sci."},{"key":"2023021008583653900_bib33","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1080\/09553002.2020.1838658","article-title":"Tumor Treating Fields (TTF) treatment enhances radiation-induced apoptosis in pancreatic cancer cells","volume":"96","author":"Jo","year":"2020","journal-title":"Int. J. Radiat. Biol."},{"key":"2023021008583653900_bib34","doi-asserted-by":"crossref","first-page":"1533033819845008","DOI":"10.1177\/1533033819845008","article-title":"Effectiveness of a fractionated therapy scheme in tumor treating fields therapy","volume":"18","author":"Jo","year":"2019","journal-title":"Technol. Cancer Res. Treat."},{"key":"2023021008583653900_bib35","doi-asserted-by":"crossref","first-page":"vi185","DOI":"10.1093\/neuonc\/nox168.750","article-title":"PDCT-06. Radio-immunotherapy using the IDO-inhibitor indoximod in combination with re-irradiation for children with progressive brain tumors in the phase 1 setting: an updated report of safety and tolerability (NCT02502708)","volume":"19","author":"Johnson","year":"2017","journal-title":"Neuro Oncol."},{"key":"2023021008583653900_bib36","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.trsl.2019.10.003","article-title":"Tumor treating fields cause replication stress and interfere with DNA replication fork maintenance: implications for cancer therapy","volume":"217","author":"Karanam","year":"2020","journal-title":"Transl. Res"},{"key":"2023021008583653900_bib37","doi-asserted-by":"crossref","first-page":"e2711","DOI":"10.1038\/cddis.2017.136","article-title":"Tumor-treating fields elicit a conditional vulnerability to ionizing radiation via the downregulation of BRCA1 signaling and reduced DNA double-strand break repair capacity in non-small cell lung cancer cell lines","volume":"8","author":"Karanam","year":"2017","journal-title":"Cell Death Dis"},{"key":"2023021008583653900_bib38","doi-asserted-by":"crossref","first-page":"185","DOI":"10.2217\/cns-2016-0049","article-title":"Tumor-treating fields plus chemotherapy versus chemotherapy alone for glioblastoma at first recurrence: a post hoc analysis of the EF-14 trial","volume":"6","author":"Kesari, S., Ram, Z.; EF-14 Trial Investigators","year":"2017","journal-title":"CNS Oncol."},{"key":"2023021008583653900_bib39","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1038\/s41420-018-0079-9","article-title":"Effects of tumor treating fields (TTFields) on glioblastoma cells are augmented by mitotic checkpoint inhibition","volume":"4","author":"Kessler","year":"2018","journal-title":"Cell Death Discov"},{"key":"2023021008583653900_bib40","doi-asserted-by":"crossref","first-page":"iii49","DOI":"10.1093\/neuonc\/noz126.174","article-title":"P11.28 Alteration of blood brain barrier (BBB) permeability by Tumor Treating Fields (TTFields) in vivo","volume":"21","author":"Ke\u00dfler","year":"2019","journal-title":"Neuro Oncol."},{"key":"2023021008583653900_bib41","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1007\/s11060-019-03361-2","article-title":"Tumor treating fields plus temozolomide for newly diagnosed glioblastoma: a sub-group analysis of Korean patients in the EF-14 phase 3 trial","volume":"146","author":"Kim","year":"2020","journal-title":"J. Neurooncol."},{"key":"2023021008583653900_bib42","doi-asserted-by":"crossref","first-page":"6630","DOI":"10.1038\/s41388-019-0882-7","article-title":"Tumor-treating fields induce autophagy by blocking the Akt2\/miR29b axis in glioblastoma cells","volume":"38","author":"Kim","year":"2019","journal-title":"Oncogene"},{"key":"2023021008583653900_bib43","doi-asserted-by":"crossref","first-page":"65125","DOI":"10.18632\/oncotarget.11372","article-title":"Tumor treating fields inhibit glioblastoma cell migration, invasion, and angiogenesis","volume":"7","author":"Kim","year":"2016","journal-title":"Oncotarget"},{"key":"2023021008583653900_bib44","first-page":"3935","article-title":"Tumor treating fields can effectively overcome trastuzumab resistant breast cancer multiplication","volume":"11","author":"Kim","year":"2021","journal-title":"Am. J. Cancer Res"},{"key":"2023021008583653900_bib45","first-page":"3475","article-title":"Sorafenib increases tumor treating fields-induced cell death in glioblastoma by inhibiting STAT3","volume":"10","author":"Kim","year":"2020","journal-title":"Am. J. Cancer Res"},{"key":"2023021008583653900_bib46","doi-asserted-by":"crossref","first-page":"1179554918825449","DOI":"10.1177\/1179554918825449","article-title":"Tumor treating fields for glioblastoma treatment: patient satisfaction and compliance with the second-generation optune\u00ae system","volume":"13","author":"Kinzel","year":"2019","journal-title":"Clin. Med. Insights Oncol"},{"key":"2023021008583653900_bib47","doi-asserted-by":"crossref","first-page":"10152","DOI":"10.1073\/pnas.0702916104","article-title":"Alternating electric fields arrest cell proliferation in animal tumor models and human brain tumors","volume":"104","author":"Kirson","year":"2007","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"2023021008583653900_bib48","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1007\/s10585-009-9262-y","article-title":"Alternating electric fields (TTFields) inhibit metastatic spread of solid tumors to the lungs","volume":"26","author":"Kirson","year":"2009","journal-title":"Clin. Exp. Metastasis"},{"key":"2023021008583653900_bib49","doi-asserted-by":"crossref","first-page":"3288","DOI":"10.1158\/0008-5472.CAN-04-0083","article-title":"Disruption of cancer cell replication by alternating electric fields","volume":"64","author":"Kirson","year":"2004","journal-title":"Cancer Res."},{"key":"2023021008583653900_bib50","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1756-6649-9-1","article-title":"Chemotherapeutic treatment efficacy and sensitivity are increased by adjuvant alternating electric fields (TTFields)","volume":"9","author":"Kirson","year":"2009","journal-title":"BMC Med. Phys."},{"key":"2023021008583653900_bib50a","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.3389\/fonc.2020.01045","article-title":"Prevention and management of dermatologic adverse events associated with tumor treating fields in patients with glioblastoma","volume":"10","author":"Lacouture","year":"2020","journal-title":"Front. Oncol."},{"key":"2023021008583653900_bib51","doi-asserted-by":"crossref","first-page":"vi195","DOI":"10.1093\/neuonc\/nox168.788","article-title":"PDTM-24. The proteogenomics of medulloblastoma","volume":"19","author":"Lau","year":"2017","journal-title":"Neuro Oncol."},{"key":"2023021008583653900_bib52","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1007\/s00432-019-03106-8","article-title":"Tumour Treating Fields (TTFields) in combination with lomustine and temozolomide in patients with newly diagnosed glioblastoma","volume":"146","author":"Lazaridis","year":"2020","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"2023021008583653900_bib53","first-page":"4582","article-title":"Tumor-treating fields as a proton beam-sensitizer for glioblastoma therapy","volume":"11","author":"Lee","year":"2021","journal-title":"Am. J. Cancer Res"},{"key":"2023021008583653900_bib54","doi-asserted-by":"crossref","DOI":"10.3390\/cancers11121999","article-title":"5-Fluorouracil as a tumor-treating field-sensitizer in colon cancer therapy","volume":"11","author":"Lee","year":"2019","journal-title":"Cancers"},{"key":"2023021008583653900_bib55","doi-asserted-by":"crossref","first-page":"12272","DOI":"10.1038\/s41598-020-68473-6","article-title":"Gene expression profiling of glioblastoma cell lines depending on TP53 status after tumor-treating fields (TTFields) treatment","volume":"10","author":"Lee","year":"2020","journal-title":"Sci. Rep."},{"key":"2023021008583653900_bib56","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1007\/s10544-018-0339-8","article-title":"Proliferation arrest, selectivity, and chemosensitivity enhancement of cancer cells treated by a low-intensity alternating electric field","volume":"20","author":"Lei","year":"2018","journal-title":"Biomed. Microdevices"},{"key":"2023021008583653900_bib57","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/s40169-016-0102-9","article-title":"Electrical stimulation towards melanoma therapy via liquid metal printed electronics on skin","volume":"5","author":"Li","year":"2016","journal-title":"Clin. Transl. Med."},{"key":"2023021008583653900_bib58","doi-asserted-by":"crossref","first-page":"748061","DOI":"10.3389\/fonc.2021.748061","article-title":"Trends in intracranial glioma incidence and mortality in the United States, 1975\u20132018","volume":"11","author":"Lin","year":"2021","journal-title":"Front. Oncol."},{"key":"2023021008583653900_bib59","doi-asserted-by":"crossref","first-page":"e33093","DOI":"10.1371\/journal.pone.0033093","article-title":"Tunneling nanotubes provide a unique conduit for intercellular transfer of cellular contents in human malignant pleural mesothelioma","volume":"7","author":"Lou","year":"2012","journal-title":"PLoS One"},{"key":"2023021008583653900_bib60","doi-asserted-by":"crossref","first-page":"715031","DOI":"10.3389\/fonc.2021.715031","article-title":"Dexamethasone treatment limits efficacy of radiation, but does not interfere with glioma cell death induced by Tumor Treating Fields","volume":"11","author":"Linder","year":"2021","journal-title":"Front. Oncol."},{"key":"2023021008583653900_bib61","doi-asserted-by":"crossref","first-page":"42","DOI":"10.3389\/fneur.2019.00042","article-title":"Triple-drug therapy with bevacizumab, irinotecan, and temozolomide plus Tumor Treating Fields for recurrent glioblastoma: a retrospective study","volume":"10","author":"Lu","year":"2019","journal-title":"Front. Neurol"},{"key":"2023021008583653900_bib62","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1053\/j.seminoncol.2014.09.010","article-title":"Clinical practice experience with NovoTTF-100ATM system for glioblastoma: the patient registry dataset (PRiDe)","volume":"41","author":"Mrugala","year":"2014","journal-title":"Semin. Oncol."},{"key":"2023021008583653900_bib63","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.lungcan.2021.08.011","article-title":"Tumor Treating Fields (TTFields) downregulate the fanconi anemia-BRCA pathway and increase the efficacy of chemotherapy in malignant pleural mesothelioma preclinical models","volume":"160","author":"Mumblat","year":"2021","journal-title":"Lung Cancer"},{"key":"2023021008583653900_bib63a","doi-asserted-by":"crossref","first-page":"2913","DOI":"10.1091\/mbc.E19-07-0362","article-title":"Septin 2\/6\/7 complexes tune microtubule plus-end growth and EB1 binding in a concentration- and filament-dependent manner","volume":"30","author":"Nakos","year":"2019","journal-title":"Mol. Biol. Cell"},{"key":"2023021008583653900_bib64","doi-asserted-by":"crossref","first-page":"110","DOI":"10.3390\/cancers11010110","article-title":"Alternating electric fields (TTFields) activate Cav1.2 channels in human glioblastoma cells","volume":"11","author":"Neuhaus","year":"2019","journal-title":"Cancers"},{"key":"2023021008583653900_bib65","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1085\/jgp.4.6.629","article-title":"The stability of bacterial suspensions: I. A convenient cell for microscopic cataphoresis experiments","volume":"4","author":"Northrop","year":"1922","journal-title":"J. Gen. Physiol."},{"key":"2023021008583653900_bib66","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1002\/acm2.13144","article-title":"Dosimetric impact of the positioning variation of tumor treating field electrodes in the PriCoTTF-phase I\/II trial","volume":"22","author":"Nour","year":"2021","journal-title":"J. Appl. Clin. Med. Phys."},{"key":"2023021008583653900_bib70","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1177\/1533033820947481","article-title":"Tumor-treating fields inhibit the metastatic potential of osteosarcoma cells","volume":"19","author":"Oh","year":"2020","journal-title":"Technol. Cancer Res. Treat."},{"key":"2023021008583653900_bib71","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.3389\/fneur.2019.01026","article-title":"Patient reported outcome (PRO) among high-grade glioma patients receiving TTFields treatment: a two center observational study","volume":"10","author":"Onken","year":"2019","journal-title":"Front. Neurol."},{"issue":"Suppl 5","key":"2023021008583653900_bib72","doi-asserted-by":"crossref","first-page":"v1","DOI":"10.1093\/neuonc\/noz150","article-title":"CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2012\u20132016","volume":"21","author":"Ostrom","year":"2019","journal-title":"Neuro Oncol."},{"key":"2023021008583653900_bib73","doi-asserted-by":"crossref","first-page":"772261","DOI":"10.3389\/fonc.2021.772261","article-title":"Health-related quality of life for patients receiving tumor treating fields for glioblastoma","volume":"11","author":"Palmer","year":"2021","journal-title":"Front. Oncol."},{"key":"2023021008583653900_bib74","doi-asserted-by":"crossref","first-page":"1533033819868225","DOI":"10.1177\/1533033819868225","article-title":"Tumor-treating fields induce RAW264.7 macrophage activation via NK-\u03baB\/MAPK signaling pathways","volume":"18","author":"Park","year":"2019","journal-title":"Technol. Cancer Res. Treat."},{"key":"2023021008583653900_bib75","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.neo.2020.11.003","article-title":"Tumor treating fields (TTFields) impairs aberrant glycolysis in glioblastoma as evaluated by [18F]DASA-23, a non-invasive probe of pyruvate kinase M2 (PKM2) expression","volume":"23","author":"Patel","year":"2021","journal-title":"Neoplasia"},{"key":"2023021008583653900_bib76","doi-asserted-by":"crossref","first-page":"107881","DOI":"10.1016\/j.bioelechem.2021.107881","article-title":"Therapy of pancreatic cancer with alternating electric fields: limitations of the method","volume":"141","author":"Pfeifer","year":"2021","journal-title":"Bioelectrochemistry"},{"key":"2023021008583653900_bib77","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.lungcan.2013.06.025","article-title":"A phase I\/II trial of Tumor Treating Fields (TTFields) therapy in combination with pemetrexed for advanced non-small cell lung cancer","volume":"81","author":"Pless","year":"2013","journal-title":"Lung Cancer"},{"key":"2023021008583653900_bib78","first-page":"e55820","article-title":"Determining the optimal inhibitory frequency for cancerous cells using Tumor Treating Fields (TTFields)","volume":"123","author":"Porat","year":"2017","journal-title":"J. Vis. Exp."},{"key":"2023021008583653900_bib79","first-page":"e58937","article-title":"The clinical application of Tumor Treating Fields therapy in glioblastoma","volume":"146","author":"Riley","year":"2019","journal-title":"J. Vis. Exp."},{"key":"2023021008583653900_bib80","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.pan.2018.10.004","article-title":"Tumor treating fields in combination with gemcitabine or gemcitabine plus nab-paclitaxel in pancreatic cancer: results of the PANOVA phase 2 study","volume":"19","author":"Rivera","year":"2019","journal-title":"Pancreatology"},{"key":"2023021008583653900_bib81","doi-asserted-by":"crossref","first-page":"034413","DOI":"10.1103\/PhysRevE.104.034413","article-title":"Modeling cell membrane electrodeformation by alternating electric fields","volume":"104","author":"Sabri","year":"2021","journal-title":"Phys. Rev. E"},{"key":"2023021008583653900_bib82","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1159\/000137713","article-title":"A pilot study with very low-intensity, intermediate-frequency electric fields in patients with locally advanced and\/or metastatic solid tumors","volume":"31","author":"Salzberg","year":"2008","journal-title":"Onkologie"},{"key":"2023021008583653900_bib83","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1186\/1471-2407-10-229","article-title":"TTFields alone and in combination with chemotherapeutic agents effectively reduce the viability of MDR cell sub-lines that over-express ABC transporters","volume":"10","author":"Schneiderman","year":"2010","journal-title":"BMC Cancer"},{"key":"2023021008583653900_bib84","doi-asserted-by":"crossref","first-page":"10034","DOI":"10.3390\/ijms150610034","article-title":"Cytotoxic autophagy in cancer therapy","volume":"15","author":"Sharma","year":"2014","journal-title":"Int. J. Mol. Sci."},{"key":"2023021008583653900_bib85","first-page":"3759","article-title":"Role of MGMT in tumor development, progression, diagnosis, treatment, and prognosis","volume":"29","author":"Sharma","year":"2009","journal-title":"Anticancer Res."},{"key":"2023021008583653900_bib86","doi-asserted-by":"crossref","first-page":"837589","DOI":"10.3389\/fonc.2022.837589","article-title":"Tumor Treating Fields suppression of ciliogenesis enhances temozolomide toxicity","volume":"12","author":"Shi","year":"2022","journal-title":"Front. Oncol."},{"key":"2023021008583653900_bib87","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1007\/s11060-020-03540-6","article-title":"Global post-marketing safety surveillance of tumor treating fields (TTFields) in patients with high-grade glioma in clinical practice","volume":"148","author":"Shi","year":"2020","journal-title":"J. Neurooncol."},{"key":"2023021008583653900_bib88","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1038\/s41419-018-1085-9","article-title":"AMPK-dependent autophagy upregulation serves as a survival mechanism in response to Tumor Treating Fields (TTFields)","volume":"9","author":"Shteingauz","year":"2018","journal-title":"Cell Death. Dis."},{"key":"2023021008583653900_bib89","doi-asserted-by":"crossref","first-page":"e2753","DOI":"10.1038\/cddis.2017.171","article-title":"Biological activity of tumor-treating fields in preclinical glioma models","volume":"8","author":"Silginer","year":"2017","journal-title":"Cell Death Dis."},{"key":"2023021008583653900_bib90","doi-asserted-by":"crossref","first-page":"101246","DOI":"10.1016\/j.xpro.2022.101246","article-title":"Protocol for live-cell imaging during Tumor Treating Fields treatment with inovitro live","volume":"3","author":"Slangen","year":"2022","journal-title":"STAR Protoc"},{"key":"2023021008583653900_bib91","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1007\/s11060-020-03466-z","article-title":"Initial experience with scalp sparing radiation with concurrent temozolomide and tumor treatment fields (SPARE) for patients with newly diagnosed glioblastoma","volume":"147","author":"Song","year":"2020","journal-title":"J. Neurooncol."},{"key":"2023021008583653900_bib92","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJMoa043330","article-title":"Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma","volume":"352","author":"Stupp","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"2023021008583653900_bib93","doi-asserted-by":"crossref","first-page":"2306","DOI":"10.1001\/jama.2017.18718","article-title":"Effect of tumor-treating fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma: a randomized clinical trial","volume":"318","author":"Stupp","year":"2017","journal-title":"JAMA"},{"key":"2023021008583653900_bib94","doi-asserted-by":"crossref","first-page":"2535","DOI":"10.1001\/jama.2015.16669","article-title":"Maintenance therapy with tumor-treating fields plus temozolomide vs. temozolomide alone for glioblastoma: a randomized clinical trial","volume":"314","author":"Stupp","year":"2015","journal-title":"JAMA"},{"key":"2023021008583653900_bib95","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.1016\/j.ejca.2012.04.011","article-title":"NovoTTF-100A versus physician's choice chemotherapy in recurrent glioblastoma: a randomised phase III trial of a novel treatment modality","volume":"48","author":"Stupp","year":"2012","journal-title":"Eur. J. Cancer"},{"key":"2023021008583653900_bib96","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1001\/jamaoncol.2017.5082","article-title":"Influence of treatment with tumor-treating fields on health-related quality of life of patients with newly diagnosed glioblastoma: a secondary analysis of a randomized clinical trial","volume":"4","author":"Taphoorn","year":"2018","journal-title":"JAMA Oncol."},{"key":"2023021008583653900_bib97","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1007\/s11060-018-03057-z","article-title":"Increased compliance with tumor treating fields therapy is prognostic for improved survival in the treatment of glioblastoma: a subgroup analysis of the EF-14 phase III trial","volume":"141","author":"Toms","year":"2019","journal-title":"J. Neurooncol."},{"key":"2023021008583653900_bib98","doi-asserted-by":"crossref","first-page":"3859","DOI":"10.3390\/cancers12123859","article-title":"Rapalink-1 targets glioblastoma stem cells and acts synergistically with tumor treating fields to reduce resistance against temozolomide","volume":"12","author":"Vargas-Toscano","year":"2020","journal-title":"Cancers"},{"key":"2023021008583653900_bib99","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.ygyno.2018.07.018","article-title":"Tumor Treating Fields in combination with paclitaxel in recurrent ovarian carcinoma: results of the INNOVATE pilot study","volume":"150","author":"Vergote","year":"2018","journal-title":"Gynecol. Oncol."},{"key":"2023021008583653900_bib100","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1007\/s00262-020-02534-7","article-title":"Tumor-treating fields (TTFields) induce immunogenic cell death resulting in enhanced antitumor efficacy when combined with anti-PD-1 therapy","volume":"69","author":"Voloshin","year":"2020","journal-title":"Cancer Immunol. Immunother."},{"key":"2023021008583653900_bib101","doi-asserted-by":"crossref","first-page":"2850","DOI":"10.1002\/ijc.30406","article-title":"Alternating electric fields (TTFields) in combination with paclitaxel are therapeutically effective against ovarian cancer cells in vitro and in vivo: TTFields in combination with paclitaxel are therapeutically effective against ovarian cancer","volume":"139","author":"Voloshin","year":"2016","journal-title":"Int. J. Cancer"},{"key":"2023021008583653900_bib102","doi-asserted-by":"crossref","first-page":"3016","DOI":"10.3390\/cancers12103016","article-title":"Tumor Treating Fields (TTFields) hinder cancer cell motility through regulation of microtubule and actin dynamics","volume":"12","author":"Voloshin","year":"2020","journal-title":"Cancers"},{"key":"2023021008583653900_bib103","doi-asserted-by":"crossref","first-page":"S14","DOI":"10.1053\/j.seminoncol.2014.09.009","article-title":"Response patterns of recurrent glioblastomas treated with tumor-treating fields","volume":"41","author":"Vymazal","year":"2014","journal-title":"Semin. Oncol."},{"key":"2023021008583653900_bib104","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1126\/science.285.5425.248","article-title":"HMG-1 as a late mediator of endotoxin lethality in mice","volume":"285","author":"Wang","year":"1999","journal-title":"Science"},{"key":"2023021008583653900_bib105","doi-asserted-by":"crossref","first-page":"e1426","DOI":"10.1634\/theoncologist.2017-0603","article-title":"Integration of tumor-treating fields into the multidisciplinary management of patients with solid malignancies","volume":"24","author":"Wang","year":"2019","journal-title":"Oncologist"},{"key":"2023021008583653900_bib106","doi-asserted-by":"crossref","first-page":"ii2","DOI":"10.1093\/annonc\/mdz072.006","article-title":"Immunomodulatory effects of Tumor Treating Fields (TTFields) on lung cancer models","volume":"30","author":"Weinberg","year":"2019","journal-title":"Ann. Oncol."},{"key":"2023021008583653900_bib107","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1038\/bjc.2015.238","article-title":"Dexamethasone exerts profound immunologic interference on treatment efficacy for recurrent glioblastoma","volume":"113","author":"Wong","year":"2015","journal-title":"Br. J. Cancer"},{"key":"2023021008583653900_bib108","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1002\/cam4.210","article-title":"Response assessment of NovoTTF-100A versus best physician's choice chemotherapy in recurrent glioblastoma","volume":"3","author":"Wong","year":"2014","journal-title":"Cancer Med."},{"key":"2023021008583653900_bib109","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1002\/cam4.421","article-title":"Clinical benefit in recurrent glioblastoma from adjuvant NovoTTF-100A and TCCC after temozolomide and bevacizumab failure: a preliminary observation","volume":"4","author":"Wong","year":"2015","journal-title":"Cancer Med."},{"key":"2023021008583653900_bib110","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1111\/cns.13441","article-title":"Evaluation of a tumor electric field treatment system in a rat model of glioma","volume":"26","author":"Wu","year":"2020","journal-title":"CNS Neurosci. Ther."},{"key":"2023021008583653900_bib111","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1111\/cns.13750","article-title":"Exploring the efficacy of tumor electric field therapy against glioblastoma: an in vivo and in vitro study","volume":"27","author":"Wu","year":"2021","journal-title":"CNS Neurosci. Ther."},{"key":"2023021008583653900_bib112","doi-asserted-by":"crossref","first-page":"8","DOI":"10.3892\/ijo.2021.5298","article-title":"Effect of duty cycles of tumor-treating fields on glioblastoma cells and normal brain organoids","volume":"60","author":"Ye","year":"2022","journal-title":"Int. J. Oncol."},{"key":"2023021008583653900_bib113","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.1038\/s41598-020-59445-x","article-title":"Barium titanate nanoparticles sensitise treatment-resistant breast cancer cells to the antitumor action of tumor-treating fields","volume":"10","author":"Yoon","year":"2020","journal-title":"Sci. Rep."},{"key":"2023021008583653900_bib114","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1007\/s11060-017-2601-y","article-title":"Health-related quality of life, cognitive screening, and functional status in a randomized phase III trial (EF-14) of tumor treating fields with temozolomide compared to temozolomide alone in newly diagnosed glioblastoma","volume":"135","author":"Zhu","year":"2017","journal-title":"J. Neurooncol."}],"container-title":["Journal of Molecular Cell Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jmcb\/advance-article-pdf\/doi\/10.1093\/jmcb\/mjac047\/45639134\/mjac047.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jmcb\/article-pdf\/14\/8\/mjac047\/49153712\/mjac047.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jmcb\/article-pdf\/14\/8\/mjac047\/49153712\/mjac047.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,10]],"date-time":"2023-02-10T09:03:09Z","timestamp":1676019789000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jmcb\/article\/doi\/10.1093\/jmcb\/mjac047\/6668799"}},"subtitle":[],"editor":[{"given":"Hua","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2022,8]]},"references-count":113,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2022,12,26]]}},"URL":"https:\/\/doi.org\/10.1093\/jmcb\/mjac047","relation":{},"ISSN":["1674-2788","1759-4685"],"issn-type":[{"value":"1674-2788","type":"print"},{"value":"1759-4685","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,8]]},"published":{"date-parts":[[2022,8]]},"article-number":"mjac047"}}